LCM
RGLS

Laurion Capital Management’s Regulus Therapeutics RGLS Stock Holding History

Laurion Capital Management’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-3,269
Closed -$408K – 1631
2017
Q4 		$408K Buy
+3,269
New +$414K ﹤0.01% 1234
2015
Q3 		– Sell
-628
Closed -$827K – 873
2015
Q2 		$827K Buy
628
+355
+130% +$573K 0.01% 443
2015
Q1 		$555K Buy
273
+75
+38% +$163K 0.01% 250
2014
Q4 		$380K Buy
+198
New +$352K 0.01% 225

Other funds holding RGLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SDIC
South Dakota Investment Council Sioux Falls, South Dakota $5.84B AUM 30.42% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AC
Ascend Capital Orinda, California $1.99B AUM 10.37% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return

Laurion Capital Management's RGLS Position: Q1 2018 in Review

Laurion Capital Management sold out of Regulus Therapeutics (RGLS) in Q1 2018, closing a stake of 3,269 shares — an estimated $408K sold.

Laurion Capital Management first reported a position in RGLS in Q4 2014 and held it in 4 quarters. The position peaked at $827K in Q2 2015. 50 funds tracked by Wall St. Rank hold RGLS as of Q1 2018.

  • Laurion Capital Management reported no remaining Regulus Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Laurion Capital Management sold 3,269 Regulus Therapeutics shares in Q1 2018, an estimated $408K.
  • Laurion Capital Management first reported a position in Regulus Therapeutics in Q4 2014 and held it in 4 quarters.
  • Laurion Capital Management's Regulus Therapeutics position peaked at $827K in Q2 2015.
  • 50 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q1 2018.

Based on Laurion Capital Management's 13F filing for Q1 2018, filed 14 May 2018.